Overview
The overarching long-term goal of the Integrative Medicine for Patient-reported Outcomes Values and Experience (IMPROVE) research program is to evaluate whether integrating a virtual mind-body programming, Integrative Medicine at Home (IM@Home), will improve patient perceived values, outcomes, and experiences as they undergo systemic cancer treatment such as chemotherapy, immunotherapy, radiotherapy, targeted agents, cytoreductive surgery.
Eligibility
Inclusion Criteria:
- Age ≥ 18 years or older
- Patients with a diagnosis of head and neck tumors, thoracic tumors, gynecological tumors, melanoma, breast cancer, or ovarian cancer
- Actively receiving systemic oncological treatment or radiotherapy, or within 4 weeks of radiotherapy completion or primary cytoreductive surgery
- Worst fatigue over the last 7 days rated 4 or greater on (0-10 scale) (Patients in the ovarian basket will not be required to meet fatigue criteria in order to be enrolled. Patients in the ovarian basket will be eligible for enrollment prior to commencement of chemotherapy)
- Karnofsky score 60 or greater
- Life expectancy greater than six months
- English speaking
Exclusion Criteria:
- Cognitive impairment that would preclude response to study assessments or require the use of Legally Authorized Representatives
- Unwilling to accept random assignment
- Concurrently enroll onto ongoing competing trials of integrative medicine interventions with symptom/toxicity as primary outcome. Note, however, patient will be allowed to enroll on other therapeutic protocols